Anjlie Gupta, MD
Ophthalmology · Las Vegas, NVNPI 1720549280
Payments from drug & device makers
What this record shows
12 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 30.6% of the total.
Across 74 payments — averaging $108.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- Alcon$2K
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$711
- Glaukos Corporation$390
- Tarsus Pharmaceuticals, Inc.$151
- plus $463 from 6 others
What the payments were for
- Travel & lodging$4,42855%
- Food & beverage$3,57345%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 22 | $2,448 |
| Alcon | 12 | $2,125 |
| AbbVie | 17 | $1,712 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $711 |
| Glaukos Corporation | 8 | $390 |
| Tarsus Pharmaceuticals, Inc. | 4 | $151 |
| Rxsight Inc | 1 | $141 |
| Amgen | 1 | $122 |
| Beaver-visitec International, Inc. | 1 | $90 |
| Dompe US, Inc. | 3 | $73 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS ELITE$1,879
- Crystalens Accommodating IOL (AT-52AO)$1,879
- enVista MX60 IOL$1,879
- Trulign IOL$1,879
- Akreos AO IOL$1,879
- Hydrus Microstent$1,662
- DURYSTA$644
- XEN GLAUCOMA TREATMENT SYSTEM$389
- iDose$155
- RXSIGHT CONTACT LENS$141
- RXSIGHT INJECTOR CARTRIDGE$141
- RXSIGHT INJECTOR HANDPIECE$141
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$141
- LIGHT ADJUSTABLE LENS (LAL)$141
- Rocklatan$133
- TEPEZZA$122
- LUMIGAN$118
- XDEMVY$117
How this compares
$8,001 in reported general payments places this provider in the 80th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 20 | $342 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Las Vegas
- Eva LiangLas Vegas$496K
- Steven LeibowitzLas Vegas$147K
- Wonchon LinLas Vegas$43K
- Ravindranath ReddyLas Vegas$30K
- Emily SchorrLas Vegas$17K
- Frank LeeLas Vegas$12K
- Tigran KostanyanLas Vegas$11K
- Tushina ReddyLas Vegas$11K
- Kent WellishLas Vegas$10K
- Eissa HannaLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.